CoChat

Small Molecule Drug Discovery for Neglected Tropical Snakebite

Clare, Rachel H., Hall, Steven R., Patel, Rohit N., Casewell, Nicholas R. · 2021 · Trends in Pharmacological Sciences
Cited by 76

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tips.2021.02.005

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 82

  1. Hotez, 2009, Rescuing the bottom billion through control of neglected tropical diseases, Lancet, 373, 1570, 10.1016/S0140-6736(09)60233-6 · DOI · Paper page
  2. Bodimeade, 2019, Neglected tropical diseases: elimination and eradication, Clin. Med. (Lond), 19, 157, 10.7861/clinmedicine.19-2-157 · doi:10.7861/clinmedicine.19-2-157
  3. De Rycker, 2018, Challenges and recent progress in drug discovery for tropical diseases, Nature, 559, 498, 10.1038/s41586-018-0327-4 · DOI · Paper page
  4. Molyneux, 2017, The London Declaration on Neglected Tropical Diseases: 5 years on, Trans. R. Soc. Trop. Med. Hyg., 375, 239
  5. Gutiérrez, 2017, Snakebite envenoming, Nat. Rev. Dis. Primers, 3, 17063, 10.1038/nrdp.2017.63 · DOI · Paper page
  6. Kasturiratne, 2008, The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths, PLoS Med., 5, 10.1371/journal.pmed.0050218 · DOI · Paper page
  7. Longbottom, 2018, Vulnerability to snakebite envenoming: a global mapping of hotspots, Lancet, 392, 673, 10.1016/S0140-6736(18)31224-8 · DOI · Paper page
  8. Harrison, 2009, Snake envenoming: a disease of poverty, PLoS Negl. Trop. Dis., 3, e569, 10.1371/journal.pntd.0000569 · DOI · Paper page
  9. Harrison, 2019, The time is now: a call for action to translate recent momentum on tackling tropical snakebite into sustained benefit for victims, Trans. R. Soc. Trop. Med. Hyg., 113, 834, 10.1093/trstmh/try134 · DOI
  10. Williams, 2019, Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming, PLoS Negl. Trop. Dis., 13, 12, 10.1371/journal.pntd.0007059 · DOI · Paper page
  11. The Lancet, 2019, Snakebite – emerging from the shadows of neglect, Lancet, 393, 2175, 10.1016/S0140-6736(19)31232-2 · doi:10.1016/s0140-6736(19)31232-2
  12. Tasoulis, 2017, A review and database of snake venom proteomes, Toxins (Basel), 9, 290, 10.3390/toxins9090290 · DOI · Paper page
  13. Slagboom, 2017, Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise, Br. J. Haematol., 177, 947, 10.1111/bjh.14591 · DOI · Paper page
  14. Ferraz, 2019, Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis, Front. Ecol. Evol., 7, 218, 10.3389/fevo.2019.00218 · DOI · Paper page
  15. Gutiérrez, 2016, Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding, Toxins (Basel), 8, 93, 10.3390/toxins8040093 · DOI · Paper page
  16. Ranawaka, 2013, Neurotoxicity in snakebite – the limits of our knowledge, PLoS Negl. Trop. Dis., 7, 10.1371/journal.pntd.0002302 · DOI · Paper page
  17. de Silva, 2016, Adverse reactions to snake antivenom, and their prevention and treatment, Br. J. Clin. Pharmacol., 81, 446, 10.1111/bcp.12739 · DOI · Paper page
  18. Lalloo, 2003, Snake antivenoms, J. Toxicol. Clin. Toxicol., 41, 277, 10.1081/CLT-120021113 · DOI · Paper page
  19. Harrison, 2017, Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005969 · DOI
  20. Brown, 2012, Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context, PLoS Negl. Trop. Dis., 6, 10.1371/journal.pntd.0001670 · doi:10.1371/journal.pntd.0001670
  21. Laustsen, 2017, Recombinant snakebite antivenoms: a cost-competitive solution to a neglected tropical disease?, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005361 · DOI
  22. Laustsen, 2019, How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?, Expert Opin. Drug Discov., 14, 1103, 10.1080/17460441.2019.1646723 · DOI
  23. Lewin, 2016, Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation, Toxins (Basel), 8, 248, 10.3390/toxins8090248 · DOI · Paper page
  24. Wang, 2018, Exploration of the inhibitory potential of varespladib for snakebite envenomation, Molecules, 23, 391, 10.3390/molecules23020391 · DOI · Paper page
  25. Layfield, 2020, Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the western diamondback rattlesnake, Crotalus atrox, Toxins (Basel), 12, 309, 10.3390/toxins12050309 · DOI · Paper page
  26. Albulescu, 2020, Preclinical validation of a repurposed metal chelator as a community-based therapeutic for hemotoxic snakebite, Sci. Transl. Med., 12, 10.1126/scitranslmed.aay8314 · DOI · Paper page
  27. Xie, 2020, Neutralizing effects of small molecule inhibitors and metal chelators on coagulopathic Viperinae snake venom toxins, Biomedicines, 8, 297, 10.3390/biomedicines8090297 · DOI
  28. Bulfone, 2018, Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite, J. Trop. Med., 2018, 4320175, 10.1155/2018/4320175 · DOI · Paper page
  29. Albulescu, 2020, A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite, Nat. Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page
  30. Williams, 2010, The Global Snake Bite Initiative: an antidote for snake bite, Lancet, 375, 89, 10.1016/S0140-6736(09)61159-4 · DOI · Paper page
  31. Williams, 2019, The urgent need to develop novel strategies for the diagnosis and treatment of snakebites, Toxins (Basel), 11, 363, 10.3390/toxins11060363 · DOI
  32. Benson, 2019, Topical and transdermal drug delivery: from simple potions to smart technologies, Curr. Drug Deliv., 16, 444, 10.2174/1567201816666190201143457 · DOI · Paper page
  33. Nicholls, 2014, Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial, JAMA, 311, 252, 10.1001/jama.2013.282836 · DOI · Paper page
  34. Bryan-Quirós, 2019, Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2, Toxicon, 157, 1, 10.1016/j.toxicon.2018.11.292 · DOI · Paper page
  35. Lewin, 2018, Delayed LY333013 (oral) and LY315920 (intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (eastern coral snake) venom, Toxins (Basel), 10, 479, 10.3390/toxins10110479 · DOI · Paper page
  36. Lewin, 2018, Delayed oral LY333013 rescues mice from highly neurotoxic, lethal doses of Papuan taipan (Oxyuranus scutellatus) venom, Toxins (Basel), 10, 380, 10.3390/toxins10100380 · DOI · Paper page
  37. Bittenbinder, 2018, Coagulotoxic cobras: clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (varespladib), Toxins (Basel), 10, 516, 10.3390/toxins10120516 · DOI · Paper page
  38. Winer, 2018, Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes, Mol. Cancer Ther., 17, 1147, 10.1158/1535-7163.MCT-17-0646 · DOI · Paper page
  39. Huxley-Jones, 2007, The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio, BMC Evol. Biol., 7, 63, 10.1186/1471-2148-7-63 · DOI
  40. Arias, 2017, Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom, Toxicon, 132, 40, 10.1016/j.toxicon.2017.04.001 · DOI · Paper page
  41. Rucavado, 2000, Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA, Am. J. Trop. Med. Hyg., 63, 313, 10.4269/ajtmh.2000.63.313 · DOI · Paper page
  42. Howes, 2007, Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators, Toxicon, 49, 734, 10.1016/j.toxicon.2006.11.020 · DOI
  43. Xie, 2020, Antivenom neutralization of coagulopathic snake venom toxins assessed by bioactivity profiling using nanofractionation analytics, Toxins (Basel), 12, 53, 10.3390/toxins12010053 · DOI
  44. Ainsworth, 2020, An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008579 · DOI
  45. Knudsen, 2020, Novel snakebite therapeutics must be tested in appropriate rescue models to robustly assess their preclinical efficacy, Toxins (Basel), 12, 528, 10.3390/toxins12090528 · DOI
  46. Bhaumik, 2020, Interventions for the management of snakebite envenoming: an overview of systematic reviews, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008727 · DOI
  47. Still, 2017, Multipurpose HTS coagulation analysis: assay development and assessment of coagulopathic snake venoms, Toxins (Basel), 9, 382, 10.3390/toxins9120382 · DOI
  48. Still, 2020, Development of high-throughput screening assays for profiling snake venom phospholipase A2 activity after chromatographic fractionation, Toxicon, 184, 28, 10.1016/j.toxicon.2020.05.022 · DOI
  49. Zdenek, 2019, A taxon-specific and high-throughput method for measuring ligand binding to nicotinic acetylcholine receptors, Toxins (Basel), 11, 600, 10.3390/toxins11100600 · DOI
  50. Papapetropoulos, 2018, Inventing new therapies without reinventing the wheel: the power of drug repurposing, Br. J. Pharmacol., 175, 165, 10.1111/bph.14081 · DOI
  51. Janes, 2018, The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis, Proc. Natl. Acad. Sci. U. S. A., 115, 10750, 10.1073/pnas.1810137115 · DOI
  52. Salvador, 2019, Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound varespladib (LY315920), Sci. Rep., 9, 17203, 10.1038/s41598-019-53755-5 · DOI · Paper page
  53. Lewin, 2013, Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation, Clin. Case Rep, 1, 7, 10.1002/ccr3.3 · doi:10.1002/ccr3.3
  54. Lynagh, 2020, Peptide inhibitors of the α-cobratoxin–nicotinic acetylcholine receptor interaction, J. Med. Chem., 63, 13709, 10.1021/acs.jmedchem.0c01202 · DOI
  55. Albulescu, 2019, A decoy-receptor approach using nicotinic acetylcholine receptor mimics reveals their potential as novel therapeutics against neurotoxic snakebite, Front. Pharmacol., 10, 848, 10.3389/fphar.2019.00848 · DOI
  56. Lim, 2019, Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method, Sci. Rep., 9, 16727, 10.1038/s41598-019-53216-z · DOI
  57. Clark, 2013, Technological and sociological advances in HTS: evolution and revolution?, Eur. Pharm. Rev., 18, 55
  58. Burrows, 2014, The role of modern drug discovery in the fight against neglected and tropical diseases, Medchemcomm, 5, 688, 10.1039/c4md00011k · DOI
  59. Taylor, 2019, Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis, Sci. Transl. Med., 11, 10.1126/scitranslmed.aau2086 · DOI
  60. von Geldern, 2019, Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity, PLoS Negl. Trop. Dis., 13, 10.1371/journal.pntd.0007159 · DOI
  61. Gustavsen, 2018, For as long as necessary: examining 30 years of MSD’s focus on achieving elimination of onchocerciasis and lymphatic filariasis, Int. Health, 10, i3, 10.1093/inthealth/ihx038 · doi:10.1093/inthealth/ihx038
  62. Boller, 2020, SnakeMap: four years of experience with a national small animal snake envenomation registry, Aust. Vet. J., 98, 442, 10.1111/avj.12993 · doi:10.1111/avj.12993
  63. Martins, 2019, Snakebite and its impact in rural communities: the need for a One Health approach, PLoS Negl. Trop. Dis., 13
  64. Turner, 2020, Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?, Vet. Parasitol., 279, 109057, 10.1016/j.vetpar.2020.109057 · DOI
  65. Guagliardo, 2020, Guinea worm in domestic dogs in Chad: a description and analysis of surveillance data, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008207 · doi:10.1371/journal.pntd.0008207
  66. Schioldann, 2018, Why snakebite patients in Myanmar seek traditional healers despite availability of biomedical care at hospitals? Community perspectives on reasons, PLoS Negl. Trop. Dis., 12, 10.1371/journal.pntd.0006299 · DOI
  67. Corley, 2016, The role of nurses and community health workers in confronting neglected tropical diseases in sub-Saharan Africa: a systematic review, PLoS Negl. Trop. Dis., 10, 10.1371/journal.pntd.0004914 · DOI
  68. Aird, 2017, Coralsnake venomics: analyses of venom gland transcriptomes and proteomes of six Brazilian taxa, Toxins (Basel), 9, 187, 10.3390/toxins9060187 · DOI
  69. Tan, 2018, Venom proteomics and antivenom neutralization for the Chinese eastern Russell’s viper, Daboia siamensis from Guangxi and Taiwan, Sci. Rep., 8, 8545, 10.1038/s41598-018-25955-y · DOI
  70. Theakston, 2000, Crisis in snake antivenom supply for Africa, Lancet, 356, 2104, 10.1016/S0140-6736(05)74319-1 · DOI · Paper page
  71. Schiermeier, 2015, Africa braced for snakebite crisis, Nature, 525, 299, 10.1038/525299a · DOI
  72. Habib, 2020, Challenges and prospects of snake antivenom supply in sub-Saharan Africa, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008374 · DOI
  73. Potet, 2019, Reviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial, PLoS Negl. Trop. Dis., 13, 10.1371/journal.pntd.0007551 · DOI
  74. Visser, 2008, Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance, Trans. R. Soc. Trop. Med. Hyg., 102, 445, 10.1016/j.trstmh.2007.11.006 · DOI
  75. Warrell, 2008, Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product – ‘What’s in a name?, Trans. R. Soc. Trop. Med. Hyg., 102, 397, 10.1016/j.trstmh.2007.12.005 · doi:10.1016/j.trstmh.2007.12.005
  76. Alirol, 2015, Antivenoms for snakebite envenoming: what is in the research pipeline?, PLoS Negl. Trop. Dis., 9, 10.1371/journal.pntd.0003896 · DOI
  77. Taylor, 2014, Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis, Parasitology, 141, 119, 10.1017/S0031182013001108 · DOI · Paper page
  78. James, 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
  79. Boussinesq, 2018, Alternative treatment strategies to accelerate the elimination of onchocerciasis, Int. Health, 10, i40, 10.1093/inthealth/ihx054 · DOI · Paper page
  80. Hong, 2019, AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis, Proc. Natl. Acad. Sci. U. S. A., 116, 1414, 10.1073/pnas.1816585116 · DOI
  81. Johnston, 2017, Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library, Sci. Adv., 3, 10.1126/sciadv.aao1551 · DOI
  82. Clare, 2019, Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides, Nat. Commun., 10, 11, 10.1038/s41467-018-07826-2 · DOI

Cited by

See all 76

Metadata

Authors
Clare, R. H., Hall, S. R., Patel, R. N., & Casewell, N. R.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2021-05
Volume
42
Issue
5
Pages
340-353
ISSN
0165-6147
Cited by
76
References
3
Language
en
Funders
  • Medical Research Council (MR/S00016X/1, 200517/Z/16/Z)
  • Liverpool School of Tropical Medicine
  • Wellcome Trust (204806/Z/16/Z)
  • Royal Society (NIF\R1\192161)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small Molecule Drug Discovery for Neglected Tropical Snakebite. https://app.cochat.ai/papers/10.1016/j.tips.2021.02.005
The paper
Clare, R. H., Hall, S. R., Patel, R. N., & Casewell, N. R. (2021). Small Molecule Drug Discovery for Neglected Tropical Snakebite. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2021.02.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.